Nuclear Factor Kappa B: A New Perspective For The Study Of Anti-Inflammatory Drugs
Keywords:
NF-kB, anti-inflammatory, glucocorticoid, inflammationAbstract
The inflammatory process involves the expression of a wide range of inflammatory proteins, which include cytokines, chemokines, enzymes that produce inflammatory mediators, receptors for inflammatory mediators and adhesion molecules, whose gene expression of many of these elements is controlled by nuclear factor kappa B. This factor belongs to a class of gene transcription factors that, in addition to regulating the expression of multiple genes involved in the inflammatory response, also controls other genes in other cell types. Several anti-inflammatory drugs, both hormonal and non-hormonal, such as corticosteroids and salicylates, have an inhibitory action on nuclear factor kappa B. In order to develop more specific and effective drugs, many research groups have been exploring the modulatory action on this factor, with the aim of controlling the inflammatory process. In this brief review we will address the most important pharmacological aspects of these inhibitors.
Downloads
References
Gallin JI, Goldstein I MM, Snyderman, R. Overview. ln: lnflammation: basic principies and clinicai correlates. New York: Raven Press; 1992. p.1-4.
Rocha e Silva M. A brief survey of the history of inflammation. 1978. Agents Actions 1994; 43(3-4): 86-90.
Robbins SL, Kumar V K, Cotran RS. Patologia estrutural e funcional. Rio de Janeiro: Guanabara Koogan; 1996. p.45-83.
Adams LB, Hibbs JB Jr, Taintor RR, Krahenbuhl JL. Microbiostatic effect of murine-activated macrophages for Toxoplasma gondii. Role for synthesis of inorganic nitrogen oxides from L-arginine. J lmmunol 1990; 144(7):2725-9.
Adams DO, Hamilton TA. Molecular basis of macrophage activation: diversity and its origins. ln: Lewis CE, McGee JOD, editors The natural lmmune System: the macrophage. New York: IRL Press; 1992. p.75-105.
Sarnes PJ. Cytokines as mediators of chronic asthma. Am J Crit Care Med 1994; 150(5 Pt 2):S42-9.
Karin M. Mitogen-activated protein kinase cascades as regulators of stress responses. Ann NY Acad Sei 1998; 30(851 ): 139-46.
Adcock IM. Glucocorticoid-regulated transcription factors. Pulm Pharmacol Ther 2001; 14(3):211- 9.
Kàdonaga JT. Eukaryotic transcription: an interlaced network of transcription factors and chromatin-modifying machines. Cell 1998; 92(3):307-13.
Struhl K, Moqtaderi Z. The TAFs in the HAT. Cell 1998; 94(1): 1-4.
Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986, 46(5): 706-16.
Baeuerle PA, Baltimore DI. kappa B: a specific inhibitor of the NF-kappa B transcription factor Science 1988; 242(4878):540-6.
Mckay LI, Cidlowski JA. Molecular contrai of immune/inflamamatory responses: interactions between nuclear factor-KB and steroid receptor-signaling pathoways. Endoc Rev 1999; 20(4):435-59.
Merika M, Williams AJ, Chen G, Collins T, Thanos D.Recruitment of CSP/p300 by the IFN-B enhanceosome is required for synergistic activation of transcription. Mol Cell 1998; 1 (2):277-87.
Barnes PJ, Adcock IM. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sei 1993; 14(12):436-41.
Blackwell TS, Christman JW. The role of nuclear factor kappa S in cytokine gene regulation. Am J Respir Cell Mol Biol 1997; 17(1 ):3-9.
Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa B: a pivotal role in the systemic response syndrome and new target for therapy. lnt Care Med 1998; 24(11): 1131-38.
Sarnes PJ, Karin M. Nuclear factor-kB a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336(15) 1166-71.
Tak TP, Firestein GS. NF-KB: a key role in inflammatory diseases. J Clin lnvest 2001; 107(1):7-11.
Penildon S. Farmacologia. ln: Kraychete D, editors. Antiinflamatórios Não-hormonais. Rio de Janeiro: Guanabara Koogan; 2002. p.556-78.
Goodman GA. As bases farmacológicas da terapêutica. ln: lnsel PA. Fármacos analgésico-antipiréticos e antiinflamatórios usados no tratamento da gota. Rio de Janeiro: Guanabara Koogan; 1996. p.450-80.
D'acquisto M, May M J. Ghosh S. lnhibition of Nuclear Factor Kappa B (NF-KS): An Emerging Theme in Anti-lnflammatory Therapies Mol lnterv 2002; 2(1 ):22-35
Almawi WY, Melemedjian OK. Negative regulation o nuclear factor-KB activation and function by glucocorticoids. J Mol End 2002; 28(2):69-78.
Doucas V, Shi Y, Miyamoto S, West A, Verma 1, Evans RM. Cytoplasmic catalytic subunit of protein kinase A mediates cross-repression by NF-kappa S and the glucocorticoid receptor. Proc Natl Acad Sei USA 2000; 97(22): 11893-8.
Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NF kappaS by interfering with serine-2 phosphorilation of the RNA polymerase li carboxy-terminal domain. Genes Dev 2000; 14(18):2315-29.
lto K, Jazrawi E, Cosio B, Sarnes PJ, Adcock IM. p65-activated histone acetyltransferease activity is repressed by glucocorticoids: Mifepristone fails to recruit HDAC2 to the p65-HATcomplex. J Biai e hem 2001; 276(32):30208-15.
Luengo MB. Medicamentos do futuro: quais são as perspectivas fu turas nas ciências farmacêuticas? Integração 2003; 23: 128-31.
May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S Selective inhibition of NF -kappa B activation by a peptide that blocks the interaction of NEMO with the lkappa B ki nase complex. Science 2000; 289(5484): 1550-4.
Fischer PM, Krauzs E, Lane DP. Cellular delivery of impermeable effect or molecules in the form of conjugates with peptides capable of mediating membrane translocation. Bioconjug Chem 2001; 12(6):825-41.
O'Dell JR. Anticytokine therapy: A new era in the treatment of rheumatoid arthritis7 N Engl J Med 1999; 340(4) 310-2.
